Skip to main content
. 2017 Jan 14;8(9):14604–14619. doi: 10.18632/oncotarget.14654

Table 1. Clinical and pathological features of MM patients analysed.

Sample Age Sex DS Stage ISS Stage Paraprotein Type % PCs Karyotype New Diagnoses Bone Disease
(A)
MM 1 (SaMMi) 81 F IA III Micromolecular, λ 20 Abnormal karyotype; chr. 1 rearrangement; t(11;14) Y N
MM 2 81 F IA III IgG/k 46 Normal Y N
MM 3 60 F IIA II IgG/k 80 Normal N Y
MM 4 77 F IIA I IgA/k 36.9 59% del(17p) Y Y
MM 5 74 M IA III IgG/k 63.8 del(13q) N N
MM 6 58 M IIIA I IgG/λ 20 Normal N Y
MM 7 72 M IIA I IgG/k 30 del(17p) Y Y
MM 8 58 M IIIA III IgA/k 16 Monosomy 13 (90%) Y Y
MM 9 71 F IIIA III IgG/k 19 Normal Y Y
MM 10 76 M IIA III IgG/k 45 IgH rearrangement N N
MM 11 74 M IIIA II IgG/λ 56 Trisomy 1q, 7, 13, 19, 22;
tetrasomy 15, del(8p), del(8p), t(2;3)
Y Y
MM 12 64 M IIIB III IgD/λ 80 Complex karyotype; t(11;14), t(1;14), del(13) Y Y
MM 13 71 F IIA I IgG/λ 30 Partial del(1); partial 1q trisomy Y Y
MM 14 60 M IIIA I IgG/k 40.6 IgH rearrangement, del(13q) N Y
MM 15 68 F IA I IgG/λ 50 Normal N N
MM 16 60 F IA I IgA/λ 51.7 Complex karyotype; del(1p);
presence of hyperdiploid clones
N Y
MM 17 67 F IIIA III Non secretory 100 Monosomy 13 (76%) Y Y
MM 18 68 F IIIA III Micromolecular, k 80 Normal N Y
MM 19 69 M IIIA II Micromolecular, k 60 del(13q), MAF+, IgH-/+ Y Y
MM 20 71 M IIIA III IgG/λ 90.1 del(Y), del(13q) N Y
MM 21 81 M IIIA II Micromolecular, λ 35 NA Y Y
MM 22 76 F IIIA I IgG/k 95 Trisomy 5, 6, 9, 11, 15, 21 Y Y
MM 29 44 M IIIB III IgA/λ 24 Complex karyotype; Monosomy 13, 14, 90% del(17p); Chr. 1 rearrangements, gain of 1q N Y
MM30 76 M IA NA IgG/k 60 Normal karyotype, IgH rearr., trisomy 17 Y N
MM31 72 F IIIA III IgG/λ 100 Complex karyotype, hyperploid; del(13q) Y N
MM32 67 M IIIA II IgG/λ 100 NA Y Y
MM33 75 M IIIB III IgG/λ 40-100 Hypodiploid , t(14;16), del(13q), gain of 1q Y N
MM34 74 M IIIB III Micromolecular, λ 100 IgH-; del(17p), gain of 1q Y Y
MM35 56 M IIIA NA IgG/λ 100 NA N Y
MM36 42 F IIIA III IgA/k 90 Normal N Y
MM37 56 M IIIA I IgA/l 100 Complex karyotype (+1, del(1), dic(1;5), -13,-16, +17. FISH: del(1q), del(13q), del FGFR N Y
MM38 70 M IIA II IgG/λ 20 NA N Y
MM39 74 M IIA II IgG/k 100 46XY; t(11;14); gain of 1q N Y
MM40 75 F IIIA II IgG/k 100 Complex karyotype; del(6p), del(17p), monosomy 10, 12, 13, 15, 16, 17 N Y
(B)
MM 8 58 M IIIA III IgA/k 16 Monosomy 13 (90%) Y Y
MM 14 60 M IIIA I IgG/k 40.6 IgH rearrangement, del(13q) N Y
MM 23 59 M IIIA I IgG/k 44 Trisomy 1, 5, 9, 18, 19, 21 Y Y
MM 24 45 F IIIA III IgG/k 86 90% MAF-/+, Monosomy 13 N Y
MM 25 54 F IIA I IgG/k 22 t(4;14), Monosomy 13 N Y
MM 26 74 F IA I IgG/k 26.4 t(14;16) N Y
MM 27 76 F IIA III IgG/λ 22.8 Normal N Y
MM 28 75 M IIB III IgG/λ 14 36% del(Y), Monosomy 13 Y Y

MM plasma cells (A) and MM BMSC (B) were isolated from bone marrow of patients listed. Clinical staging was performed according to Durie-Salmon criteria and according to the International Staging System (ISS; albumin levels ≤ or > 35 g/L; β2-microglobulin levels ≤ or > 3.5 mg/L). All features are reported as data at diagnosis. M = Male, F = Female, DS = Durie-Salmon, ISS = International Staging System, PC = Plasma Cell, Y = Yes/Present, N = No/Absent, NA = Not Available.